



Incorporation of Odne Inc.

Dübendorf, 16. November 2023. Today, Odne announces the incorporation of its subsidiary Odne Inc in the US.

The incorporation of Odne Inc. marks an important milestone in the history of the company. Since OdneFill the first light-curing endodontic filler (developed, patented, and produced by Odne™) was successfully cleared by the FDA in July 2023. The company is now preparing for market launch in the USA in 2024.

Andreas Schmocker, CEO, commented: “We are thrilled that we achieved FDA approval for Odne®Fill, which is the basis to establish our US subsidiary and expand our business. Now we can pursue our US launch as planned. After many years of research and development, we are looking forward to improving patients' lives and providing this innovative and smart endodontic solution to the dental market. We are committed to continuing our research and providing innovative solutions to the endodontics industry.”

Odne is looking forward to the exciting developments and further successes that this new phase of expansion will bring.

Our US office is based at:

Odne Inc.
361 E Water St.
Gettysburg, PA 17325
United States

About Odne: Odne, formerly known as Lumendo, has its roots in a groundbreaking collaboration between two renowned Swiss institutions: The Swiss Federal Institutes of Technology in Lausanne and Zürich (EPFL & ETH Zürich). Founded in 2018, our journey began by licensing cutting-edge technology assets from these esteemed institutes. Over time we have developed our product portfolio in collaboration with top institutions and partners in North America, Europe, South America and Asia. Our first commercial market is the United States of America.

Odne AG represents a harmonious synergy of Swiss precision and academic excellence. Our company is committed to pioneering the future of endodontics through advanced technology and innovative solutions. Endodontics, the field of dental medicine that deals with root canal treatments, has been marred by complexity and unpredictability. Odne AG is on a mission to change that.

Root canal treatments have long posed challenges for dentists, with traditionally low success rates ranging from 46% to 91%¹. With over 60 million annual treatments worldwide, these failures result in mutli-billion healthcare costs.

¹ S. Friedman, “Prognosis of initial endodontic therapy,” Endod. Top., vol. 2, no. 1, pp. 59–88, Jul. 2002.



Odne's technology platform addresses these issues by offering treatment options for both dentists and their patients. Our products, slated for launch in 2024, tackle problems such as the obturation in complex morphologies.

Disclaimer: Odne's endodontic filler, Odne®Fill, is cleared for use in the U.S.A only. All other Odne devices are currently in development and have not received clinical approval in any jurisdiction.

For further information contact:

Odne AG
Ringstrasse 14
8600 Dübendorf
Switzerland

info@odne.co
www.odne.co

